What’s Happening
Chatter
- “Results not posted” – is there some way to combat this?
- Phase separation pseudoscience
- FDA’s plan to boost biosimilar drugs could stall at the patent office
- Peptide vendor from China to Germany?
- [hiring] ai-biotech research expert
- Help in making Anti-Fog Solution
- [Research] AI Hypothesis Engine (MedDiscovery) proposes a highly novel MRSA therapy using ‘Crystallization Inhibitors’ (Layer 3 Cross-Domain Analogy). Full Preclinical Protocol & Budget included for critique.
- Finished my thesis and I think I’m in shock
- What’s the current challenges that biotech faces when it comes to building creative startups
- EMG Prostethic Arm
- eli lilly tech intern
- vent pharm
- Any biotech marketers transitioned out of science?
- Clinical Research & Primary Care
- Offered a lateral move (QA to Manufacturing Operations) at my biotech company. Unsure to take it or not.
Charts
Research
Longboard Pharma and Bexisaserin
Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time of writing. Today we will take a closer look at this clinical stage pharma company, and its primary asset, bexicaserin.
…